Kristiansen, K. Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein–coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function. Pharmacol. Ther. 103, 21–80 (2004).
Kobilka, B.K. G protein–coupled receptor structure and activation. Biochim. Biophys. Acta 1768, 794–807 (2007).
Lagerström, M.C. & Schiöth, H.B. Structural diversity of G protein–coupled receptors and significance for drug discovery. Nat. Rev. Drug Discov. 7, 339–357 (2008).
Scarborough, R.M. et al. Tethered ligand agonist peptides. Structural requirements for thrombin receptor activation reveal mechanism of proteolytic unmasking of agonist function. J. Biol. Chem. 267, 13146–13149 (1992).
Vassart, G., Pardo, L. & Costagliola, S. A molecular dissection of the glycoprotein hormone receptors. Trends Biochem. Sci. 29, 119–126 (2004).
Breit, A. et al. Alternative G protein coupling and biased agonism: new insights into melanocortin-4 receptor signalling. Mol. Cell. Endocrinol. 331, 232–240 (2011).
Bromberg, Y., Overton, J., Vaisse, C., Leibel, R.L. & Rost, B. In silico mutagenesis: a case study of the melanocortin 4 receptor. FASEB J. 23, 3059–3069 (2009).
Srinivasan, S. et al. Constitutive activity of the melanocortin-4 receptor is maintained by its N-terminal domain and plays a role in energy homeostasis in humans. J. Clin. Invest. 114, 1158–1164 (2004).
Seifert, R. & Wenzel-Seifert, K. Constitutive activity of G-protein–coupled receptors: cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch. Pharmacol. 366, 381–416 (2002).
Tolle, V. & Low, M.J. In vivo evidence for inverse agonism of Agouti-related peptide in the central nervous system of proopiomelanocortin-deficient mice. Diabetes 57, 86–94 (2008).
Peter, J.C. et al. Antibodies against the melanocortin-4 receptor act as inverse agonists in vitro and in vivo. Am. J. Physiol. Regul. Integr. Comp. Physiol. 292, R2151–R2158 (2007).
Ollmann, M.M. et al. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 278, 135–138 (1997).
Fan, W., Boston, B.A., Kesterson, R.A., Hruby, V.J. & Cone, R.D. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 385, 165–168 (1997).
Nijenhuis, W.A., Oosterom, J. & Adan, R.A. AgRP(83–132) acts as an inverse agonist on the human-melanocortin-4 receptor. Mol. Endocrinol. 15, 164–171 (2001).
Chai, B.X. et al. Inverse agonist activity of agouti and agouti-related protein. Peptides 24, 603–609 (2003).
Costa, T. & Herz, A. Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc. Natl. Acad. Sci. USA 86, 7321–7325 (1989).
Kenakin, T. Efficacy as a vector: the relative prevalence and paucity of inverse agonism. Mol. Pharmacol. 65, 2–11 (2004).
Patel, M.P. et al. Loop-swapped chimeras of the agouti-related protein and the agouti signaling protein identify contacts required for melanocortin 1 receptor selectivity and antagonism. J. Mol. Biol. 404, 45–55 (2010).
Ballesteros, J.A. & Weinstein, H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein–coupled receptors. Methods Neurosci. 25, 366–428 (1995).
Lubrano-Berthelier, C. et al. Melanocortin 4 receptor mutations in a large cohort of severely obese adults: prevalence, functional classification, genotype-phenotype relationship, and lack of association with binge eating. J. Clin. Endocrinol. Metab. 91, 1811–1818 (2006).
Calton, M.A. et al. Association of functionally significant Melanocortin-4 but not Melanocortin-3 receptor mutations with severe adult obesity in a large North American case-control study. Hum. Mol. Genet. 18, 1140–1147 (2009).
Haskell-Luevano, C., Cone, R.D., Monck, E.K. & Wan, Y.P. Structure activity studies of the melanocortin-4 receptor by in vitro mutagenesis: identification of agouti-related protein (AGRP), melanocortin agonist and synthetic peptide antagonist interaction determinants. Biochemistry 40, 6164–6179 (2001).
Jongejan, A. et al. Linking ligand binding to histamine H1 receptor activation. Nat. Chem. Biol. 1, 98–103 (2005).
Pellissier, L.P. et al. Conformational toggle switches implicated in basal constitutive and agonist-induced activated states of 5–HT4 receptors. Mol. Pharmacol. 75, 982–990 (2009).
Holst, B. et al. A conserved aromatic lock for the tryptophan rotameric switch in TM-VI of seven-transmembrane receptors. J. Biol. Chem. 285, 3973–3985 (2010).
Choe, H.W. et al. Crystal structure of metarhodopsin II. Nature 471, 651–655 (2011).
Standfuss, J. et al. The structural basis of agonist-induced activation in constitutively active rhodopsin. Nature 471, 656–660 (2011).
Xu, F. et al. Structure of an agonist-bound human A2A adenosine receptor. Science 332, 322–327 (2011).
Warne, T. et al. The structural basis for agonist and partial agonist action on a β1-adrenergic receptor. Nature 469, 241–244 (2011).
Rasmussen, S.G. et al. Structure of a nanobody-stabilized active state of the β2 adrenoceptor. Nature 469, 175–180 (2011).
Rosenbaum, D.M. et al. Structure and function of an irreversible agonist-β2 adrenoceptor complex. Nature 469, 236–240 (2011).
Shi, L. et al. β2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. J. Biol. Chem. 277, 40989–40996 (2002).
Swaminath, G. et al. Probing the 2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists. J. Biol. Chem. 280, 22165–22171 (2005).
Civelli, O. GPCR deorphanizations: the novel, the known and the unexpected transmitters. Trends Pharmacol. Sci. 26, 15–19 (2005).
Bond, R.A. & Ijzerman, A.P. Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery. Trends Pharmacol. Sci. 27, 92–96 (2006).
Chen, G. et al. Use of constitutive G protein–coupled receptor activity for drug discovery. Mol. Pharmacol. 57, 125–134 (2000).
Behan, D.P. & Chalmers, D.T. The use of constitutively active receptors for drug discovery at the G protein–coupled receptor gene pool. Curr. Opin. Drug Discov. Devel. 4, 548–560 (2001).
Toyooka, M., Tujii, T. & Takeda, S. The N-terminal domain of GPR61, an orphan G-protein–coupled receptor, is essential for its constitutive activity. J. Neurosci. Res. 87, 1329–1333 (2009).
Lubrano-Berthelier, C. et al. Intracellular retention is a common characteristic of childhood obesity–associated MC4R mutations. Hum. Mol. Genet. 12, 145–153 (2003).
Vaisse, C. et al. Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J. Clin. Invest. 106, 253–262 (2000).